Summary

The regenerative medicine market is projected to reach USD 62.69 billion by 2031 from USD 23.90 billion in 2026, at a CAGR of 21.3% during the forecast period. Factors such as the wide scope in new therapeutic areas and collaborations and partnerships by major market players are predicted to uplift the market in the coming years. Additionally, the rise in the focus on personalized medicine and rising regenerative medicine regulatory approvals is expected to provide lucrative market growth. However, lack of long-term data, ethical & legal concerns, and high cost of treatments are expected to restrict the market growth.

The cell therapy segment held the dominant share in the regenerative medicine market.
Based on product, the global regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {autologous therapy, allogenic therapy] cell-based immunotherapy products), and tissue engineering products. The dominance of the cell therapy segment is driven by the growing adoption of stem cell therapies and cell-based immunotherapies, including CAR-T therapies, along with increasing clinical applications across oncology, musculoskeletal disorders, autoimmune diseases, and other therapeutic areas.

The musculoskeletal disorders segment accounted for the largest share of the market in 2025.
Based on therapeutic area, the regenerative medicine market is segmented into oncology, musculoskeletal disorders, neurology, ophthalmology, dermatology & wound care, cardiovascular diseases, and others. The musculoskeletal disorders segment accounted for the largest share of the regenerative medicines market in 2025, driven by the high prevalence of orthopedic and degenerative conditions and the growing adoption of regenerative therapies for cartilage repair, bone regeneration, tendon and ligament injuries, and osteoarthritis.

Asia Pacific is projected to register significant growth in the global regenerative medicine market.
The regenerative medicine market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is anticipated to grow at a significant CAGR during the forecast period. High burden of chronic diseases, growing per capita income, and the rising demand for new technologies are expected to support the regenerative medicine market growth in the region.

Primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side - 80%, and Demand Side - 20%
- By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives - 25%
- By Region: North America - 55%, Europe -10%, Asia-Pacific - 20%, Latin America - 10%, MEA - 5%

List of Companies Profiled in the Report:
- Novartis AG (Switzerland)
- Biogen, Inc. (US)
- Sarepta Therapeutics, Inc. (US)
- Gilead Sciences, Inc. (US)
- Amgen Inc. (US)
- Smith+Nephew (UK)
- MEDIPOST Co., Ltd. (Korea)
- JCR Pharmaceuticals Co., Ltd. (Japan)
- CORESTEM, Inc. (South Korea)
- Vericel Corporation (US)
- MIMEDX Group, Inc. (US)
- Organogenesis Inc. (US)
- Medtronic (Ireland)
- Bristol-Myers Squibb Company (US)
- Orthocell Ltd. (Australia)
- Mesoblast Ltd. (Australia)
- BioRestorative Therapies, Inc. (US)
- Pluristem Therapeutics Inc. (US)
- TEGOSCIENCE (South Korea)
- ANTEROGEN.CO., LTD. (South Korea)
- Bluebird Bio, Inc. (US)
- Stempeutics Research Pvt Ltd. (India)
- Sibiono GeneTech Co., Ltd. (China)
- Aspect Biosystems Ltd. (Canada)
- Athersys, Inc. (US)

Research Coverage:
This report provides a detailed picture of the regenerative medicine market. It aims to estimate the size and future growth potential of the market across different segments, such as product, therapeutic area, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
- Analysis of key drivers (Growing focus on personalized medicine, Steep rise in regulatory approvals in regenerative medicine, Rising collaborations and partnerships by major market players, Increasing scope in new therapeutic areas), restraints (Lack of long-term data, Ethical and legal concerns and high cost of treatments), opportunities (Integration with artificial intelligence and big data, Harnessing the potential of 3D printing, Growing number of organ transplants) and challenges (Lack of favorable reimbursement policies across various regions) influencing the growth of the regenerative medicine market
- Product Development/Innovation: Detailed insights on newly launched products of the regenerative medicine market
- Market Development: Comprehensive information about lucrative markets – the report analyses the regenerative medicine market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), and CORESTEM, Inc. (South Korea), among others

ページTOPに戻る

Table of Contents

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 STUDY SCOPE 29
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 29
1.3.2 INCLUSIONS & EXCLUSIONS 30
1.3.3 YEARS CONSIDERED 30
1.3.4 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 31
1.5 SUMMARY OF CHANGES 31

2 EXECUTIVE SUMMARY 32
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 32
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 34
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 35
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 36
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 37

3 PREMIUM INSIGHTS 38
3.1 REGENERATIVE MEDICINE MARKET OVERVIEW 38
3.2 REGENERATIVE MEDICINE MARKET, BY TYPE & REGION 39
3.3 REGENERATIVE MEDICINE MARKET: GEOGRAPHIC SNAPSHOT 40
3.4 REGENERATIVE MEDICINE MARKET SHARE, BY PRODUCT 2026 VS 2031 40

4 MARKET OVERVIEW 41
4.1 INTRODUCTION 41
4.2 MARKET DYNAMICS 41
4.2.1 DRIVERS 42
4.2.1.1 Expanding clinical pipeline and increasing commercialization of regenerative therapies 42
4.2.1.2 Broadening therapeutic applications of regenerative medicine 43
4.2.1.3 Increased investment and strategic partnerships 43
4.2.1.4 Advancing regulatory support for regenerative therapies 43
4.2.2 RESTRAINTS 44
4.2.2.1 High treatment costs and reimbursement constraints 44
4.2.2.2 Long-term safety and durability uncertainties 44
4.2.3 OPPORTUNITIES 45
4.2.3.1 Allogeneic and iPSC-derived "off-the-shelf" cell therapies 45
4.2.3.2 Clinical translation of tissue engineering and 3D bioprinting 45
4.2.4 CHALLENGES 45
4.2.4.1 Shortage of specialized manufacturing infrastructure and skilled personnel 45
4.3 UNMET NEEDS AND WHITE SPACES 46
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 46
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 47

5 INDUSTRY TRENDS 48
5.1 PORTER’S FIVE FORCES ANALYSIS 48
5.1.1 THREAT OF NEW ENTRANTS 49
5.1.2 THREAT OF SUBSTITUTES 49
5.1.3 BARGAINING POWER OF BUYERS 49
5.1.4 BARGAINING POWER OF SUPPLIERS 49
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 49
5.2 MACROECONOMIC OUTLOOK 50
5.2.1 INTRODUCTION 50
5.2.2 GDP TRENDS AND FORECAST 50
5.2.3 TRENDS IN GLOBAL REGENERATIVE MEDICINE MARKET 50
5.3 VALUE CHAIN ANALYSIS 51
5.4 ECOSYSTEM ANALYSIS 52
5.5 PRICING ANALYSIS 54
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER (2023–2025) 54
5.5.2 AVERAGE SELLING PRICE, BY REGION (2025) 55
5.6 KEY CONFERENCES & EVENTS 55
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 56
5.8 INVESTMENT/FUNDING ACTIVITY 57
5.9 CASE STUDY ANALYSIS 58
5.10 IMPACT OF 2025 US TARIFFS—REGENERATIVE MEDICINE MARKET 59
5.10.1 INTRODUCTION 59
5.10.2 KEY TARIFF RATES 59
5.10.3 PRICE IMPACT ANALYSIS 60
5.10.4 IMPACT ON COUNTRIES/REGIONS 61
5.10.4.1 North America 61
5.10.4.2 Europe 61
5.10.4.3 Asia Pacific 62
5.10.5 IMPACT ON END-USE INDUSTRIES 62
5.10.5.1 Hospitals 62
5.10.5.2 Specialty clinics and cancer centers 63
5.10.5.3 Other specialty care settings 63

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 64
6.1 KEY EMERGING TECHNOLOGIES 64
6.1.1 AI-DRIVEN CELL & GENE THERAPY DEVELOPMENT 64
6.1.2 SMART BIOMATERIALS & INJECTABLE SCAFFOLDS 64
6.2 ADJACENT TECHNOLOGIES 65
6.2.1 ORGANOID & ORGAN-ON-CHIP TECHNOLOGIES 65
6.2.2 ADVANCED IMAGING & CELL CHARACTERIZATION TECHNOLOGIES 65
6.3 COMPLEMENTARY TECHNOLOGIES 66
6.3.1 BIOREACTORS & ADVANCED CELL CULTURE SYSTEMS 66
6.3.2 CELL EXPANSION & CELL PROCESSING TECHNOLOGIES 66
6.4 TECHNOLOGY/PRODUCT ROADMAP 66
6.5 PIPELINE ANALYSIS 67
6.6 FUTURE APPLICATIONS 68
6.7 IMPACT OF AI/GEN AI ON REGENERATIVE MEDICINE MARKET 68
6.7.1 TOP USE CASES AND MARKET POTENTIAL 69
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN REGENERATIVE
MEDICINE MARKET 70
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT
ON MARKET PLAYERS 70
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN REGENERATIVE
MEDICINE MARKET 71

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 72
7.1 REGIONAL REGULATIONS AND COMPLIANCE 72
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 72
7.1.2 INDUSTRY STANDARDS 75
7.2 SUSTAINABILITY INITIATIVES 76
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 76
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS 77

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 79
8.1 DECISION-MAKING PROCESS 79
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 79
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
8.2.2 KEY BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS,
BY END USER 80
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 82
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 82
8.5 MARKET PROFITABILITY 83

9 REGENERATIVE MEDICINE MARKET, BY PRODUCT 84
9.1 INTRODUCTION 85
9.2 CELL THERAPY 85
9.2.1 STEM CELL THERAPY 88
9.2.1.1 Cell transplantations 91
9.2.1.1.1 Potential of Allo-SCT in treating AML to
drive segmental growth 91
9.2.1.2 Stem cell therapy products 94
9.2.1.2.1 Autologous therapy 97
9.2.1.2.1.1 Low risk of post-treatment complications to support segment growth 97
9.2.1.2.2 Allogeneic therapy 100
9.2.1.2.2.1 High potential in disease treatment to ensure demand and development 100
9.2.2 CELL-BASED IMMUNOTHERAPY 103
9.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth 103
9.3 GENE THERAPY 106
9.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET 106
9.4 TISSUE ENGINEERING 109
9.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET 109

10 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA 113
10.1 INTRODUCTION 114
10.2 ONCOLOGY 114
10.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET 114
10.3 MUSCULOSKELETAL DISORDERS 119
10.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET 119
10.4 DERMATOLOGY & WOUND CARE 122
10.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET 122
10.5 CARDIOVASCULAR DISEASES 125
10.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH 125
10.6 OPHTHALMOLOGY 128
10.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH 128
10.7 NEUROLOGY 132
10.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH 132
10.8 OTHER THERAPEUTIC AREAS 135

11 REGENERATIVE MEDICINE MARKET, BY REGION 139
11.1 INTRODUCTION 140
11.2 NORTH AMERICA 140
11.2.1 US 144
11.2.1.1 Rising number of pipeline products for regenerative medicine
to drive market 144
11.2.2 CANADA 147
11.2.2.1 Rising government initiatives for regenerative medicine research
to drive market 147
11.3 EUROPE 150
11.3.1 GERMANY 153
11.3.1.1 Rising focus on clinical research and patent approvals to drive market 153
11.3.2 UK 155
11.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market 155
11.3.3 FRANCE 158
11.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline 158
11.3.4 ITALY 160
11.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market 160
11.3.5 SPAIN 163
11.3.5.1 Favorable regulatory environment to drive product pipeline 163
11.3.6 REST OF EUROPE 165
11.4 ASIA PACIFIC 168
11.4.1 CHINA 172
11.4.1.1 Favorable government support for development of regenerative medicine to drive market 172
11.4.2 JAPAN 175
11.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies 175
11.4.3 INDIA 177
11.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth 177
11.4.4 SOUTH KOREA 180
11.4.4.1 Strong research base and availability of funds to support market growth 180
11.4.5 AUSTRALIA 182
11.4.5.1 Increasing incidence of sports injuries to support market growth 182
11.4.6 REST OF ASIA PACIFIC 184
11.5 LATIN AMERICA 187
11.5.1 BRAZIL 189
11.5.1.1 Gradual increase in pharmaceutical R&D to support market growth 189
11.5.2 REST OF LATIN AMERICA 191
11.6 MIDDLE EAST 193
11.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS 193
11.7 AFRICA 195
11.7.1 RISING COLLABORATIONS TO SUPPORT MARKET GROWTH IN COMING YEARS 195

12 COMPETITIVE LANDSCAPE 199
12.1 INTRODUCTION 199
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 199
12.3 REVENUE ANALYSIS, 2023–2025 200
12.4 MARKET SHARE ANALYSIS, 2025 201
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 203
12.5.1 STARS 203
12.5.2 EMERGING LEADERS 203
12.5.3 PERVASIVE PLAYERS 204
12.5.4 PARTICIPANTS 204
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 205
12.5.5.1 Company footprint 205
12.5.6 REGION FOOTPRINT 206
12.5.7 PRODUCT FOOTPRINT 207
12.5.8 THERAPEUTIC AREA FOOTPRINT 208
12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025 209
12.6.1 PROGRESSIVE COMPANIES 209
12.6.2 RESPONSIVE COMPANIES 209
12.6.3 DYNAMIC COMPANIES 209
12.6.4 STARTING BLOCKS 209
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 211
12.6.5.1 Detailed list of key startups/SMEs 211
12.6.5.2 Competitive benchmarking of startups/SMEs 212
12.7 COMPANY VALUATION AND FINANCIAL METRICS 213
12.7.1 VALUATION OF KEY PLAYERS 213
12.7.2 FINANCIAL METRICS OF KEY PLAYERS (PRODUCTS) 213
12.8 RAND/PRODUCT COMPARATIVE ANALYSIS 214
12.9 COMPETITIVE SCENARIO 215
12.9.1 PRODUCT LAUNCHES 215
12.9.2 DEALS 216
12.9.3 EXPANSIONS 217

13 COMPANY PROFILES 218
13.1 KEY MARKET PLAYERS 218
13.1.1 NOVARTIS AG 218
13.1.1.1 Business overview 218
13.1.1.2 Products offered 220
13.1.1.3 Recent developments 220
13.1.1.3.1 Product approvals 220
13.1.1.3.2 Deals 221
13.1.1.3.3 Expansions 221
13.1.1.4 MnM view 222
13.1.1.4.1 Key Strengths/Right to win 222
13.1.1.4.2 Strategic choices made 222
13.1.1.4.3 Weaknesses & competitive threats 222
13.1.2 GILEAD SCIENCES, INC. 223
13.1.2.1 Business overview 223
13.1.2.2 Products offered 224
13.1.2.3 Recent developments 225
13.1.2.3.1 Product approvals 225
13.1.2.3.2 Deals 225
13.1.2.4 MnM view 226
13.1.2.4.1 Key strengths 226
13.1.2.4.2 Strategic choices 226
13.1.2.4.3 Weaknesses & competitive threats 226
13.1.3 SAREPTA THERAPEUTICS, INC. 227
13.1.3.1 Business overview 227
13.1.3.2 Products offered 228
13.1.3.3 Recent developments 229
13.1.3.3.1 Product launches & approvals 229
13.1.3.3.2 Deals 229
13.1.3.4 MnM view 230
13.1.3.4.1 Key strengths 230
13.1.3.4.2 Strategic choices 230
13.1.3.4.3 Weaknesses & competitive threats 230
13.1.4 AMGEN, INC. 231
13.1.4.1 Business overview 231
13.1.4.2 Products offered 232
13.1.4.3 Recent developments 233
13.1.4.3.1 Deals 233
13.1.4.4 MnM view 233
13.1.4.4.1 Key strengths 233
13.1.4.4.2 Strategic choices 233
13.1.4.4.3 Weaknesses & competitive threats 233
13.1.5 JOHNSON & JOHNSON 234
13.1.5.1 Business overview 234
13.1.5.2 Products offered 235
13.1.5.3 Recent developments 236
13.1.5.3.1 Product approvals 236
13.1.5.3.2 Deals 236
13.1.5.4 MnM view 237
13.1.5.4.1 Key Strengths/Right to win 237
13.1.5.4.2 Strategic choices made 237
13.1.5.4.3 Weaknesses & competitive threats 237
13.1.6 BIOGEN INC. 238
13.1.6.1 Business overview 238
13.1.6.2 Products offered 239
13.1.6.3 Recent developments 240
13.1.6.3.1 Product approvals 240
13.1.6.3.2 Expansions 240
13.1.7 SMITH+NEPHEW 241
13.1.7.1 Business overview 241
13.1.7.2 Products offered 242
13.1.8 MEDIPOST CO., LTD. 243
13.1.8.1 Business overview 243
13.1.8.2 Products offered 244
13.1.8.3 Recent developments 245
13.1.8.3.1 Deals 245
13.1.8.3.2 Other developments 245
13.1.9 JCR PHARMACEUTICALS CO., LTD. 246
13.1.9.1 Business overview 246
13.1.9.2 Products offered 248
13.1.10 CORESTEM, INC. 249
13.1.10.1 Business overview 249
13.1.10.2 Products offered 249
13.1.10.3 Product pipeline 250
13.1.11 VERICEL CORPORATION 251
13.1.11.1 Business overview 251
13.1.11.2 Products offered 252
13.1.11.3 Recent developments 253
13.1.11.3.1 Product approvals 253
13.1.12 MIMEDX GROUP, INC. 254
13.1.12.1 Business overview 254
13.1.12.2 Products offered 255
13.1.12.3 Recent developments 256
13.1.12.3.1 Product launches 256
13.1.12.3.2 Deals 257
13.1.13 ORGANOGENESIS INC. 258
13.1.13.1 Business overview 258
13.1.13.2 Products offered 259
13.1.13.3 Recent developments 260
13.1.13.3.1 Deals 260
13.1.14 MEDTRONIC 261
13.1.14.1 Business overview 261
13.1.14.2 Products offered 262
13.1.14.3 Recent developments 263
13.1.14.3.1 Deals 263
13.1.15 BRISTOL-MYERS SQUIBB COMPANY 264
13.1.15.1 Business overview 264
13.1.15.2 Products offered 266
13.1.15.3 Recent developments 266
13.1.15.3.1 Product approvals 266
13.1.15.3.2 Deals 267
13.1.16 AUTOLUS THERAPEUTICS 268
13.1.16.1 Business overview 268
13.1.16.2 Products offered 269
13.1.16.3 Recent developments 269
13.1.16.3.1 Product approvals 269
13.1.16.3.2 Deals 269
13.2 OTHER PLAYERS 270
13.2.1 ORTHOCELL LTD. 270
13.2.2 MESOBLAST LTD. 271
13.2.3 BIORESTORATIVE THERAPIES, INC. 272
13.2.4 PLURISTEM THERAPEUTICS INC. 272
13.2.5 TEGOSCIENCE 273
13.2.6 ANTEROGEN. CO., LTD. 273
13.2.7 BLUEBIRD BIO, INC. 274
13.2.8 STEMPEUTICS RESEARCH PVT. LTD. 274
13.2.9 SIBIONO GENETECH CO. LTD. 275
13.2.10 ASPECT BIOSYSTEMS 275

14 RESEARCH METHODOLOGY 277
14.1 RESEARCH DATA 277
14.1.1 SECONDARY DATA 278
14.1.2 PRIMARY DATA 279
14.2 MARKET SIZE ESTIMATION 280
14.2.1 PRIMARY INSIGHTS 284
14.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE MARKET 284
14.3 MARKET BREAKDOWN & DATA TRIANGULATION 287
14.4 STUDY ASSUMPTIONS 288
14.5 RISK ANALYSIS 288

15 APPENDIX 289
15.1 DISCUSSION GUIDE 289
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 292
15.3 CUSTOMIZATION OPTIONS 294
15.4 RELATED REPORTS 294
15.5 AUTHOR DETAILS 295

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 REGENERATIVE MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE 29.
FIGURE 2 REGENERATIVE MEDICINE MARKET: YEARS CONSIDERED 30.
FIGURE 3 MARKET SCENARIO 33.
FIGURE 4 GLOBAL REGENERATIVE MEDICINE MARKET, 2024–2031 33.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN REGENERATIVE.
MEDICINE MARKET, 2023–2026 34.
FIGURE 6 DISRUPTIONS INFLUENCING THE GROWTH OF REGENERATIVE MEDICINE MARKET 35.
FIGURE 7 HIGH-GROWTH SEGMENTS IN REGENERATIVE MEDICINE MARKET, 2026–2031 36.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN REGENERATIVE MEDICINE MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 37.
FIGURE 9 GROWING ADOPTION OF CELL & GENE THERAPY TO AID GROWTH 38.
FIGURE 10 CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN NORTH AMERICA IN 2025 39.
FIGURE 11 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 40.
FIGURE 12 CELL THERAPY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 40.
FIGURE 13 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS,.
OPPORTUNITIES, AND CHALLENGES 41.
FIGURE 14 REGENERATIVE MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS 48.
FIGURE 15 REGENERATIVE MEDICINE MARKET: VALUE CHAIN ANALYSIS 51.
FIGURE 16 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS 53.
FIGURE 17 REGENERATIVE MEDICINE MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 56.
FIGURE 18 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 57.
FIGURE 19 IMPACT OF AI/GEN AI ON REGENERATIVE MEDICINE MARKET 69.
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 79.
FIGURE 21 KEY BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS, BY END USER 80.
FIGURE 22 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT 141.
FIGURE 23 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT 169.
FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS, 2023–2025 (USD MILLION) 200.
FIGURE 25 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 201.
FIGURE 26 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 204.
FIGURE 27 REGENERATIVE MEDICINE MARKET: COMPANY FOOTPRINT 205.
FIGURE 28 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 210.
FIGURE 29 EV/EBITDA OF KEY PLAYERS 213.
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK.
BETA OF KEY PLAYERS 213.
FIGURE 31 REGENERATIVE MEDICINES PRODUCTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF REGENERATIVE MEDICINES INSTRUMENTS 214.
FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2025) 219.
FIGURE 33 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025) 224.
FIGURE 34 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2025) 228.
FIGURE 35 AMGEN, INC.: COMPANY SNAPSHOT (2025) 232.
FIGURE 36 JOHNSON & JOHNSON: COMPANY SNAPSHOT 235.
FIGURE 37 BIOGEN INC.: COMPANY SNAPSHOT (2025) 239.
FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2025) 242.
FIGURE 39 MEDIPOST CO., LTD.: COMPANY SNAPSHOT (2023) 243.
FIGURE 40 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2025) 247.
FIGURE 41 VERICEL CORPORATION: COMPANY SNAPSHOT (2025) 252.
FIGURE 42 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2025) 254.
FIGURE 43 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2025) 258.
FIGURE 44 MEDTRONIC: COMPANY SNAPSHOT (2025) 262.
FIGURE 45 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2025) 265.
FIGURE 46 AUTOLUS THERAPEUTICS COMPANY: COMPANY SNAPSHOT (2025) 268.
FIGURE 47 RESEARCH DESIGN 277.
FIGURE 48 BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET 279.
FIGURE 49 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS:.
REGENERATIVE MEDICINE MARKET, 2025 280.
FIGURE 50 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2025 281.
FIGURE 51 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2025 281.
FIGURE 52 PRODUCT-BASED REVENUE ANALYSIS, 2025 283.
FIGURE 53 VALIDATION FROM PRIMARY EXPERTS 284.
FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 284.
FIGURE 55 CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET 285.
FIGURE 56 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET 286.
FIGURE 57 DATA TRIANGULATION METHODOLOGY 287.
TABLE 1 REGENERATIVE MEDICINE MARKET: IMPACT ANALYSIS 42.
TABLE 2 REGENERATIVE MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 48.
TABLE 3 REGENERATIVE MEDICINE MARKET: ROLE IN ECOSYSTEM 53.
TABLE 4 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,.
2023–2025 (USD) 55.
TABLE 5 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD) 55.
TABLE 6 REGENERATIVE MEDICINE MARKET: KEY CONFERENCES & EVENTS, 2026–2027 55.
TABLE 7 REDUCING CAR-T MANUFACTURING TURNAROUND TIME FOR YESCARTA 58.
TABLE 8 EXPANDING CAR-T MANUFACTURING CAPACITY TO MEET GLOBAL.
CARVYKTI DEMAND 58.
TABLE 9 EXPANDING BIOMANUFACTURING CAPACITY FOR REGENERATIVE.
TISSUE PRODUCTS 59.
TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES 59.
TABLE 11 INDICATIVE LIST OF PIPELINE PRODUCTS IN PHASE 3, 2025 67.
TABLE 12 CASE STUDIES OF AI IMPLEMENTATION IN REGENERATIVE MEDICINE MARKET 70.
TABLE 13 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN REGENERATIVE.
MEDICINE MARKET 71.
TABLE 14 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 72.
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 80.
TABLE 16 KEY BUYING CRITERIA, BY END USER 81.
TABLE 17 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 85.
TABLE 18 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 86.
TABLE 19 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION,.
2023–2031 (USD MILLION) 86.
TABLE 20 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 87.
TABLE 21 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 87.
TABLE 22 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 88.
TABLE 23 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 88.
TABLE 24 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 89.
TABLE 25 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION,.
2023–2031 (USD MILLION) 89.
TABLE 26 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 90.
TABLE 27 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 90.
TABLE 28 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 91.
TABLE 29 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 91.
TABLE 30 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2023–2031 (USD MILLION) 92.
TABLE 31 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 92.
TABLE 32 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS,.
BY COUNTRY, 2023–2031 (USD MILLION) 93.
TABLE 33 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 93.
TABLE 34 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023–2031 (USD MILLION) 94.
TABLE 35 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS,.
BY TYPE, 2023–2031 (USD MILLION) 94.
TABLE 36 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS,.
BY REGION, 2023–2031 (USD MILLION) 95.
TABLE 37 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023–2031 (USD MILLION) 95.
TABLE 38 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023–2031 (USD MILLION) 96.
TABLE 39 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023–2031 (USD MILLION) 96.
TABLE 40 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023–2031 (USD MILLION) 97.
TABLE 41 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2023–2031 (USD MILLION) 98.
TABLE 42 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 98.
TABLE 43 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 99.
TABLE 44 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 99.
TABLE 45 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 100.
TABLE 46 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2023–2031 (USD MILLION) 101.
TABLE 47 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 101.
TABLE 48 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 102.
TABLE 49 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 102.
TABLE 50 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 103.
TABLE 51 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY,.
BY REGION, 2023–2031 (USD MILLION) 104.
TABLE 52 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 104.
TABLE 53 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 105.
TABLE 54 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 105.
TABLE 55 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 106.
TABLE 56 APPROVED GENE THERAPIES, 2022 107.
TABLE 57 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION,.
2023–2031 (USD MILLION) 107.
TABLE 58 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 107.
TABLE 59 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2023–2031 (USD MILLION) 108.
TABLE 60 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 108.
TABLE 61 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY,.
BY COUNTRY, 2023–2031 (USD MILLION) 109.
TABLE 62 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2023–2031 (USD MILLION) 110.
TABLE 63 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023–2031 (USD MILLION) 110.
TABLE 64 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING,.
BY COUNTRY, 2023–2031 (USD MILLION) 111.
TABLE 65 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING,.
BY COUNTRY, 2023–2031 (USD MILLION) 111.
TABLE 66 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023–2031 (USD MILLION) 112.
TABLE 67 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 114.
TABLE 68 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS 115.
TABLE 69 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION,.
2023–2031 (USD MILLION) 117.
TABLE 70 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 117.
TABLE 71 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 118.
TABLE 72 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 118.
TABLE 73 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 119.
TABLE 74 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS,.
BY REGION, 2023–2031 (USD MILLION) 120.
TABLE 75 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 120.
TABLE 76 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 121.
TABLE 77 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 121.
TABLE 78 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 79 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS 123.
TABLE 80 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE,.
BY REGION, 2023–2031 (USD MILLION) 123.
TABLE 81 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023–2031 (USD MILLION) 124.
TABLE 82 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023–2031 (USD MILLION) 124.
TABLE 83 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 84 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023–2031 (USD MILLION) 125.
TABLE 85 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2031 (USD MILLION) 126.
TABLE 86 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 127.
TABLE 87 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 127.
TABLE 88 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 89 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 90 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY 129.
TABLE 91 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2023–2031 (USD MILLION) 130.
TABLE 92 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 93 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 94 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 95 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 96 REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION,.
2023–2031 (USD MILLION) 133.
TABLE 97 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 133.
TABLE 98 EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 99 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 100 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 101 REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2031 (USD MILLION) 136.
TABLE 102 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2031 (USD MILLION) 136.
TABLE 103 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS,.
BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 104 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 105 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 106 REGENERATIVE MEDICINE MARKET, BY REGION, 2023–2031 (USD MILLION) 140.
TABLE 107 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 142.
TABLE 108 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 142.
TABLE 109 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 143.
TABLE 110 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 143.
TABLE 111 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 143.
TABLE 112 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 144.
TABLE 113 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 145.
TABLE 114 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 145.
TABLE 115 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 146.
TABLE 116 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS,.
BY TYPE, 2023–2031 (USD MILLION) 146.
TABLE 117 US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 147.
TABLE 118 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 148.
TABLE 119 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 148.
TABLE 120 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 149.
TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 149.
TABLE 122 CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 150.
TABLE 123 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 151.
TABLE 124 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 151.
TABLE 125 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 151.
TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 152.
TABLE 127 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 152.
TABLE 128 EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 153.
TABLE 129 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 154.
TABLE 130 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 154.
TABLE 131 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 154.
TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 155.
TABLE 133 GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 155.
TABLE 134 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 156.
TABLE 135 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 157.
TABLE 136 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 157.
TABLE 137 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS,.
BY TYPE, 2023–2031 (USD MILLION) 157.
TABLE 138 UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 158.
TABLE 139 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 159.
TABLE 140 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 159.
TABLE 141 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 159.
TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 160.
TABLE 143 FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 160.
TABLE 144 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 161.
TABLE 145 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 161.
TABLE 146 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 162.
TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 162.
TABLE 148 ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 163.
TABLE 149 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 164.
TABLE 150 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 164.
TABLE 151 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 164.
TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 165.
TABLE 153 SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 165.
TABLE 154 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 166.
TABLE 155 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 166.
TABLE 156 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 167.
TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 167.
TABLE 158 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 168.
TABLE 159 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 170.
TABLE 160 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 170.
TABLE 161 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 171.
TABLE 162 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 171.
TABLE 163 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 171.
TABLE 164 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 172.
TABLE 165 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 173.
TABLE 166 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 173.
TABLE 167 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 173.
TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 174.
TABLE 169 CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 174.
TABLE 170 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 175.
TABLE 171 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 176.
TABLE 172 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 176.
TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 176.
TABLE 174 JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 177.
TABLE 175 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 178.
TABLE 176 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 178.
TABLE 177 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 178.
TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 179.
TABLE 179 INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 179.
TABLE 180 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 180.
TABLE 181 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 181.
TABLE 182 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 181.
TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 181.
TABLE 184 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 182.
TABLE 185 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 183.
TABLE 186 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 183.
TABLE 187 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 183.
TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 184.
TABLE 189 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 184.
TABLE 190 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 185.
TABLE 191 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 185.
TABLE 192 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 185.
TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 186.
TABLE 194 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 186.
TABLE 195 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 187.
TABLE 196 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 187.
TABLE 197 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 188.
TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 188.
TABLE 199 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 188.
TABLE 200 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 189.
TABLE 201 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 189.
TABLE 202 BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 190.
TABLE 203 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 190.
TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 190.
TABLE 205 BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 191.
TABLE 206 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 191.
TABLE 207 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 192.
TABLE 208 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 192.
TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 192.
TABLE 210 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 193.
TABLE 211 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 194.
TABLE 212 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 194.
TABLE 213 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,.
BY TYPE, 2023–2031 (USD MILLION) 194.
TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 195.
TABLE 215 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 195.
TABLE 216 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,.
2023–2031 (USD MILLION) 196.
TABLE 217 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE,.
2023–2031 (USD MILLION) 196.
TABLE 218 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023–2031 (USD MILLION) 197.
TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023–2031 (USD MILLION) 197.
TABLE 220 AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,.
2023–2031 (USD MILLION) 198.
TABLE 221 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN THE REGENERATIVE MEDICINE MARKET 199.
TABLE 222 REGENERATIVE MEDICINE MARKET: DEGREE OF COMPETITION 202.
TABLE 223 REGENERATIVE MEDICINE MARKET: REGION FOOTPRINT 206.
TABLE 224 REGENERATIVE MEDICINE MARKET: PRODUCT FOOTPRINT 207.
TABLE 225 REGENERATIVE MEDICINE MARKET: THERAPEUTIC AREA FOOTPRINT 208.
TABLE 226 REGENERATIVE MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES 211.
TABLE 227 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 212.
TABLE 228 REGENERATIVE MEDICINE MARKET: PRODUCT LAUNCHES,.
JANUARY 2023–SEPTEMBER 2026 215.
TABLE 229 REGENERATIVE MEDICINE MARKET: DEALS, JANUARY 2023–SEPTEMBER 2026 216.
TABLE 230 REGENERATIVE MEDICINE MARKET: EXPANSIONS, JANUARY.
2023–SEPTEMBER 2026 217.
TABLE 231 NOVARTIS AG: COMPANY OVERVIEW 218.
TABLE 232 NOVARTIS AG: PRODUCTS OFFERED 220.
TABLE 233 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023–SEPTEMBER 2026 220.
TABLE 234 NOVARTIS AG: DEALS, JANUARY 2023–SEPTEMBER 2026 221.
TABLE 235 NOVARTIS AG: EXPANSIONS, JANUARY 2023–SEPTEMBER 2026 221.
TABLE 236 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 223.
TABLE 237 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 224.
TABLE 238 GILEAD SCIENCES, INC.: PRODUCT APPROVALS,.
JANUARY 2023–SEPTEMBER 2026 225.
TABLE 239 GILEAD SCIENCES, INC.: DEALS, JANUARY 2023–SEPTEMBER 2026 225.
TABLE 240 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 227.
TABLE 241 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED 228.
TABLE 242 SAREPTA THERAPEUTICS, INC.: PRODUCT LAUNCHES & APPROVALS,.
JANUARY 2023–SEPTEMBER 2026 229.
TABLE 243 SAREPTA THERAPEUTICS, INC.: DEALS, JANUARY 2023–SEPTEMBER 2026 229.
TABLE 244 AMGEN, INC.: COMPANY OVERVIEW 231.
TABLE 245 AMGEN, INC.: PRODUCTS OFFERED 232.
TABLE 246 AMGEN, INC.: DEALS, JANUARY 2023–SEPTEMBER 2026 233.
TABLE 247 JOHNSON & JOHNSON: COMPANY OVERVIEW 234.
TABLE 248 JOHNSON & JOHNSON: PRODUCTS OFFERED 235.
TABLE 249 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2023–SEPTEMBER 2026 236.
TABLE 250 JOHNSON & JOHNSON: DEALS, JANUARY 2023–SEPTEMBER 2026 236.
TABLE 251 BIOGEN INC.: COMPANY OVERVIEW 238.
TABLE 252 BIOGEN INC.: PRODUCTS OFFERED 239.
TABLE 253 BIOGEN INC.: PRODUCT APPROVALS, JANUARY 2023–SEPTEMBER 2026 240.
TABLE 254 BIOGEN INC.: EXPANSIONS, JANUARY 2023–SEPTEMBER 2026 240.
TABLE 255 SMITH+NEPHEW: COMPANY OVERVIEW 241.
TABLE 256 SMITH+NEPHEW: PRODUCTS OFFERED 242.
TABLE 257 MEDIPOST CO., LTD.: COMPANY OVERVIEW 243.
TABLE 258 MEDIPOST: PRODUCTS OFFERED 244.
TABLE 259 PRODUCT PIPELINE 244.
TABLE 260 MEDIPOST: DEALS, JANUARY 2023–SEPTEMBER 2026 245.
TABLE 261 MEDIPOST: OTHER DEVELOPMENTS, JANUARY 2023–SEPTEMBER 2026 245.
TABLE 262 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW 246.
TABLE 263 JCR PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED 248.
TABLE 264 CORESTEM, INC.: COMPANY OVERVIEW 249.
TABLE 265 CORESTEM, INC.: PRODUCTS OFFERED 249.
TABLE 266 VERICEL CORPORATION: COMPANY OVERVIEW 251.
TABLE 267 VERICEL CORPORATION: PRODUCTS OFFERED 252.
TABLE 268 VERICEL CORPORATION: PRODUCT APPROVALS,.
JANUARY 2023–SEPTEMBER 2026 253.
TABLE 269 MIMEDX GROUP, INC.: COMPANY OVERVIEW 254.
TABLE 270 MIMEDX GROUP, INC.: PRODUCTS OFFERED 255.
TABLE 271 MIMEDX GROUP, INC.: PRODUCT LAUNCHES, JANUARY 2023–SEPTEMBER 2026 256.
TABLE 273 ORGANOGENESIS INC.: COMPANY OVERVIEW 258.
TABLE 274 ORGANOGENESIS INC.: PRODUCTS OFFERED 259.
TABLE 275 ORGANOGENESIS INC.: PRODUCT LAUNCHES, JANUARY 2023–SEPTEMBER 2026 260.
TABLE 276 MEDTRONIC: COMPANY OVERVIEW 261.
TABLE 277 MEDTRONIC: PRODUCTS OFFERED 262.
TABLE 278 MEDTRONIC: PRODUCT LAUNCHES, JANUARY 2023–SEPTEMBER 2026 263.
TABLE 279 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW 264.
TABLE 280 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED 266.
TABLE 281 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS,.
JANUARY 2023–SEPTEMBER 2026 266.
TABLE 282 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2023–SEPTEMBER 2026 267.
TABLE 283 AUTOLUS THERAPEUTICS: COMPANY OVERVIEW 268.
TABLE 284 AUTOLUS THERAPEUTICS: PRODUCTS OFFERED 269.
TABLE 285 AUTOLUS THERAPEUTICS: PRODUCT APPROVALS,.
JANUARY 2023–SEPTEMBER 2026 269.
TABLE 286 AUTOLUS THERAPEUTICS: DEALS, JANUARY 2023–SEPTEMBER 2026 269.
TABLE 287 ORTHOCELL LTD.: COMPANY OVERVIEW 270.
TABLE 288 MESOBLAST LTD.: COMPANY OVERVIEW 271.
TABLE 289 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW 272.
TABLE 290 PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW 272.
TABLE 291 TEGOSCIENCE: COMPANY OVERVIEW 273.
TABLE 292 ANTEROGEN. CO., LTD.: COMPANY OVERVIEW 273.
TABLE 293 BLUEBIRD BIO, INC.: COMPANY OVERVIEW 274.
TABLE 294 STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW 274.
TABLE 295 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW 275.
TABLE 296 ASPECT BIOSYSTEMS: COMPANY OVERVIEW 275.
TABLE 297 ATHERSYS, INC.: COMPANY OVERVIEW 276.